OABIW 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-06

• Our proprietary technologies are joined with and leverage a suite of in silico, artificial intelligence and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities.

• Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes. OmniAb technologies are designed to be leveraged for the discovery of a variety of next-generation…

• •xPloration revenue increased primarily as a result of instrument sales and related consumables.

• •Royalty revenue increased primarily due to higher net sales from partners’ product sales in China.

• •License and milestone revenue increased primarily due to a $18.3 million increase in milestone revenue.

相对上期删除的文字 · 来源:10-Q · 2026-05-07

• Our proprietary technologies are joined with and leverage a suite of in silico, artificial intelligence and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on i…

• •xPloration revenue and royalty revenue remained relatively consistent period over period.

• •Research and development expenses consist of (1) personnel related expenses, including salaries, benefits and share-based compensation, (2) external expenses, including third-party costs for goods and services such as lab supplies and contract research, and (3) facility and other overhead expenses,…

• •General and administrative expenses declined primarily due to lower personnel expenses related to lower share-based compensation expense and headcount and lower legal fees.

• •Other operating income, net decreased primarily due to a lower reduction in contingent liabilities attributed to changes in certain ion channel programs, which was partially offset by an increase in royalty expense.